Cardiovascular Systems Stock
Your prediction
Pros and Cons of Cardiovascular Systems in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cardiovascular Systems vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cardiovascular Systems | - | - | - | - | - | - | - |
| Atricure Inc. | - | 4.819% | 29.851% | -43.871% | -43.871% | -43.871% | -9.845% |
| Orasure Tech | -2.750% | 0.000% | 7.614% | -45.078% | -38.012% | -56.557% | -80.000% |
| SI-BONE Inc | -1.260% | -5.917% | 8.163% | 25.197% | 22.308% | - | - |
News
Boston Sci Q2 Revenue Up 23%
Boston Scientific (NYSE:BSX), a leading medical device maker known for its heart and surgical products, released second-quarter results on July 23, 2025. Revenue reached $5.06 billion for Q2 2025
Boston Sci Q2 Revenue Up 23 Percent
Boston Scientific (NYSE:BSX), a leader in medical devices for cardiovascular and surgical markets, reported its second-quarter 2025 results on July 23, 2025. The company posted revenue and earnings